A lower systemic immune-inflammation index level is associated with response to cardiac resynchronization theraphy

Abstract

Aim: The systemic immune-inflammation index (SII), a novel inflammation-based biomarker combining platelet, neutrophil and lymphocyte counts, has been shown to be associated with worse clinical outcomes in several malignancies. However, the relationship between SII and response to cardiac resynchronization theraphy (CRT) has not been evaluated yet. The aim of this study was to investigate the association between SII and response to CRT in patients with heart failure (HF). Material and Methods: A total of 88 patients (54.5% male; mean age 58.9±12.9 years) who underwent CRT device implantation were included in the study. Baseline clinical, demographic, laboratory and echocardiographic data of patients' were recorded. An echocardiographic CRT response was defined as a decrease in left ventricular end-systolic volume of ≥15% and/or absolute increase of 5% in left ventricular ejection fraction (LVEF) at 6-month follow-up after CRT implantation. Results: Among included patients, a total of 51 (57.9%) patients were defined as ''responders'' after 6 months of CRT implantation. Lymphocyte count, LVEF and QRS width were significantly higher in responders compared to those responders. In addition, baseline creatinine and SII levels were significantly lower in responders than nonresponders. Multivariate logistic regression analysis showed that a SII of ≤973.3, LVEF and QRS width were independent predictors for response to CRT in the study population. Conclusion: SII may be used as a novel, simple and reliable inflammatory biomarker in the prediction of response to CRT in patients with HF.